{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:01:48Z","timestamp":1784790108399,"version":"3.55.0"},"reference-count":177,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-026-01911-y","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:48:24Z","timestamp":1784782104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From synaptic development to degeneration: a narrative review of small molecule strategies targeting alpha-synuclein in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Leanne","family":"Khoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuen Yen","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cien Leong","family":"Chye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Yee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Tze","family":"Tsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soi Moi","family":"Chye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"issue":"1","key":"1911_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich A, Schmitz Y, Fari\u00f1as I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo J, MG, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice Lacking \u03b1-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System. Neuron 25(1):239\u2013252","journal-title":"Neuron"},{"issue":"1","key":"1911_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13024-023-00675-8","volume":"18","author":"SG Allen","year":"2023","unstructured":"Allen SG, Meade RM, White LL, Mason JM (2023) Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease. Mol Neurodegener 18(1):80","journal-title":"Mol Neurodegener"},{"issue":"12","key":"1911_CR3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/humu.21582","volume":"32","author":"DC Angeles","year":"2011","unstructured":"Angeles DC, Gan BH, Onstead L, Zhao Y, Lim KL, Dachsel J, Melrose H, Farrer M, Wszolek ZK, Dickson DW, Tan EK (2011) Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat 32(12):1390\u20131397","journal-title":"Hum Mutat"},{"issue":"1","key":"1911_CR4","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","volume":"13","author":"L Antonschmidt","year":"2022","unstructured":"Antonschmidt L, Matthes D, Dervi\u015fo\u011flu R, Frieg B, Dienemann C, Leonov A, Nimerovsky E, Sant V, Ryazanov S, Giese A, Schr\u00f6der GF, Becker S, de Groot BL, Griesinger C, Andreas LB (2022) The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils. Nat Commun 13(1):5385","journal-title":"Nat Commun"},{"issue":"6","key":"1911_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and Treatment of Parkinson Disease: A Review. JAMA 323(6):548\u2013560","journal-title":"JAMA"},{"key":"1911_CR6","doi-asserted-by":"crossref","unstructured":"Arnsten A, Baudry M (2023) Targeting Calpain-2 for Alzheimer\u2019s Disease Treatment. Med Res Arch 11(2)","DOI":"10.18103\/mra.v11i2.3487"},{"issue":"1","key":"1911_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.bbrc.2013.02.065","volume":"433","author":"L Baird","year":"2013","unstructured":"Baird L, Dinkova-Kostova AT (2013) Diffusion dynamics of the Keap1\u2013Cullin3 interaction in single live cells. Biochem Biophys Res Commun 433(1):58\u201365","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"1911_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.4155\/fmc-2018-0436","volume":"11","author":"WA Banks","year":"2019","unstructured":"Banks WA, Greig NH (2019) Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide. Future Med Chem 11(6):489\u2013493","journal-title":"Future Med Chem"},{"key":"1911_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0820","author":"MAS Baptista","year":"2020","unstructured":"Baptista MAS, Merchant K, Barrett T, Bhargava S, Bryce DK, Ellis JM, Estrada AA, Fell MJ, Fiske BK, Fuji RN, Galatsis P, Henry AG, Hill S, Hirst W, Houle C, Kennedy ME, Liu X, Maddess ML, Markgraf C, Mei H (2020) LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aav0820","journal-title":"Sci Transl Med"},{"key":"1911_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","volume":"31","author":"GES Batiha","year":"2023","unstructured":"Batiha GES, Al-kuraishy HM, Al-Gareeb AI et al (2023) SIRT1 pathway in Parkinson\u2019s disease: a faraway snapshot but so close. Inflammopharmacol 31:37\u201356","journal-title":"Inflammopharmacol"},{"issue":"6","key":"1911_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1007\/s13311-023-01407-y","volume":"20","author":"M Baudry","year":"2023","unstructured":"Baudry M, Luo YL, Bi X (2023) Calpain-2 inhibitors as therapy for traumatic brain injury. Neurotherapeutics 20(6):1592\u20131602","journal-title":"Neurotherapeutics"},{"key":"1911_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1181","author":"M Baudry","year":"2024","unstructured":"Baudry M, Wang Y, Bi X, Luo YL, Wang Z, Kamal Z, Shirokov A, Sullivan E, Lagasca D, Khalil H, Lee G, Fosnaugh K, Bey P, Mehdi S, Coulter G (2024) Identification and neuroprotective properties of NA-184, a calpain\u20102 inhibitor. Pharmacol Res Perspect. https:\/\/doi.org\/10.1002\/prp2.1181","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"1911_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"JT Bendor","year":"2013","unstructured":"Bendor JT, Logan TP, Edwards RH (2013) The Function of \u03b1-Synuclein. Neuron 79(6):1044\u20131066","journal-title":"Neuron"},{"issue":"3","key":"1911_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/jnc.13570","volume":"137","author":"MJ Benskey","year":"2016","unstructured":"Benskey MJ, Perez RG, Manfredsson FP (2016) The contribution of alpha synuclein to neuronal survival and function \u2013 Implications for Parkinson\u2019s disease. J Neurochem 137(3):331\u2013359","journal-title":"J Neurochem"},{"issue":"16","key":"1911_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells14161272","volume":"14","author":"SE Berman","year":"2025","unstructured":"Berman SE, Siderowf AD (2025) Current status of \u03b1-synuclein biomarkers and the need for \u03b1-synuclein PET tracers. Cells 14(16):1272","journal-title":"Cells"},{"key":"1911_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01399","author":"LD Bernal-Conde","year":"2020","unstructured":"Bernal-Conde LD, Ramos-Acevedo R, Reyes-Hern\u00e1ndez MA, Balbuena-Olvera AJ, Morales-Moreno ID, Arg\u00fcero-S\u00e1nchez R, Sch\u00fcle B, Guerra-Crespo M (2020) Alpha-synuclein physiology and pathology: a perspective on cellular structures and organelles. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2019.01399","journal-title":"Front Neurosci"},{"issue":"3","key":"1911_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3390\/biomedicines12030549","volume":"12","author":"A Bougea","year":"2024","unstructured":"Bougea A (2024) Some Novel Therapies in Parkinson\u2019s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature. Biomedicines 12(3):549","journal-title":"Biomedicines"},{"key":"1911_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2023.1197853","author":"V Brembati","year":"2023","unstructured":"Brembati V, Faustini G, Longhena F, Bellucci A (2023) Alpha synuclein post translational modifications: potential targets for Parkinson\u2019s disease therapy? Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2023.1197853","journal-title":"Front Mol Neurosci"},{"key":"1911_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00080","author":"JC Bridi","year":"2018","unstructured":"Bridi JC, Hirth F (2018) Mechanisms of \u03b1-synuclein induced synaptopathy in Parkinson\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2018.00080","journal-title":"Front Neurosci"},{"issue":"Pt B","key":"1911_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.expneurol.2017.10.003","volume":"298","author":"P Brundin","year":"2017","unstructured":"Brundin P, Dave KD, Kordower JH (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298(Pt B):225\u2013235","journal-title":"Exp Neurol"},{"issue":"4","key":"1911_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JPD-150642","volume":"5","author":"J Burr\u00e9","year":"2015","unstructured":"Burr\u00e9 J (2015) The Synaptic Function of \u03b1-Synuclein. J Parkinsons Dis 5(4):699\u2013713","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"1911_CR22","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1093\/brain\/awad150","volume":"146","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Di Lazzaro G, Marino G, Campanelli F, Ghiglieri V (2023a) Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease. Brain 146(9):3587\u20133597","journal-title":"Brain"},{"issue":"3","key":"1911_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023b) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):1\u201316","journal-title":"Cell Death Dis"},{"issue":"3","key":"1911_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3233\/JPD-191683","volume":"9","author":"S Cerri","year":"2019","unstructured":"Cerri S, Mus L, Blandini F (2019) Parkinson\u2019s disease in women and men: What\u2019s the difference? J Parkinsons Dis 9(3):501\u2013515","journal-title":"J Parkinsons Dis"},{"issue":"17","key":"1911_CR25","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1021\/acschemneuro.3c00234","volume":"14","author":"M Chaturvedi","year":"2023","unstructured":"Chaturvedi M, Raj R, Yadav SK, Srivastava T, Devi S, Dharmadana D, Val\u00e9ry C, Sharma SK, Kumar D, Priya S (2023) Implications of in vitro multi-serine phosphorylation of alpha-synuclein in aggregation and cytotoxicity. ACS Chem Neurosci 14(17):3103\u20133112","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"1911_CR26","doi-asserted-by":"publisher","first-page":"e0116919","DOI":"10.1371\/journal.pone.0116919","volume":"10","author":"X Chen","year":"2015","unstructured":"Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Abdul Rauf N, Wang H, Silverman RB, Ayata C, Maxwell M, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG (2015) The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson\u2019s disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLoS ONE 10(1):e0116919","journal-title":"PLoS ONE"},{"issue":"1","key":"1911_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-021-00497-6","volume":"16","author":"KS Chen","year":"2021","unstructured":"Chen KS, Menezes K, Rodgers JB, O\u2019Hara DM, Tran N, Fujisawa K, Ishikura S, Khodaei S, Chau H, Cranston A, Kapadia M, Pawar G, Ping S, Krizus A, Lacoste A, Spangler S, Visanji NP, Marras C, Majbour NK, El-Agnaf OMA (2021) Small molecule inhibitors of \u03b1-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol Neurodegener 16(1):77","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1911_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13024-022-00560-w","volume":"17","author":"K Chen","year":"2022","unstructured":"Chen K, Martens YA, Meneses A, Ryu DH, Lu W, Raulin AC, Li F, Zhao J, Chen Y, Jin Y, Linares C, Goodwin M, Li Y, Liu C-C, Kanekiyo T, Holtzman DM, Golde TE, Bu G, Zhao N (2022) LRP1 is a neuronal receptor for \u03b1-synuclein uptake and spread. Mol Neurodegener 17(1):56","journal-title":"Mol Neurodegener"},{"issue":"4","key":"1911_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom11040612","volume":"11","author":"FC Church","year":"2021","unstructured":"Church FC (2021) Treatment options for motor and non-motor symptoms of Parkinson\u2019s disease. Biomolecules 11(4):612","journal-title":"Biomolecules"},{"issue":"21","key":"1911_CR30","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM (2010) Synergistic interactions between A\u03b2, tau, and \u03b1-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30(21):7281\u20137289","journal-title":"J Neurosci"},{"issue":"7","key":"1911_CR31","first-page":"902","volume":"206","author":"T Courtin","year":"2022","unstructured":"Courtin T, Brice A (2022) Les progr\u00e8s dans la g\u00e9n\u00e9tique de la maladie de Parkinson: quelles le\u00e7ons en tirer pour la pratique clinique\u202f? Bull Acad Natl Med 206(7):902\u2013908","journal-title":"Bull Acad Natl Med"},{"issue":"5","key":"1911_CR32","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","volume":"149","author":"N Cremades","year":"2012","unstructured":"Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TPJ, Dobson CM, Klenerman D (2012) Direct observation of the interconversion of normal and toxic forms of \u03b1-synuclein. Cell 149(5):1048\u20131059","journal-title":"Cell"},{"issue":"1","key":"1911_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41573-023-00194-7","volume":"23","author":"S Crunkhorn","year":"2023","unstructured":"Crunkhorn S (2023) USP30 inhibition protects dopaminergic neurons. Nat Rev Drug Discov 23(1):22","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1911_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/biom5020435","volume":"5","author":"T da Lopes","year":"2015","unstructured":"da Lopes T, Villar-Piqu\u00e9 A, Outeiro TF (2015) The interplay between alpha-synuclein clearance and spreading. Biomolecules 5(2):435\u2013471","journal-title":"Biomolecules"},{"issue":"3","key":"1911_CR35","doi-asserted-by":"publisher","first-page":"e2000374","DOI":"10.1371\/journal.pbio.2000374","volume":"15","author":"RM de Oliveira","year":"2017","unstructured":"de Oliveira RM, Miranda HV, Francelle L, Pinho R, Szeg\u0151 \u00c9M, Martinho R, Munari F, L\u00e1zaro DF, Moniot S, Guerreiro P, Fonseca-Ornelas L, Marijanovic Z, Antas P, Gerhardt E, Enguita FJ, Fauvet B, Penque D, Pais TF, Tong Q, Becker S (2017) The mechanism of sirtuin 2-mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease. PLoS Biol 15(3):e2000374","journal-title":"PLoS Biol"},{"issue":"15","key":"1911_CR36","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1093\/hmg\/ddu112","volume":"23","author":"M Diepenbroek","year":"2014","unstructured":"Diepenbroek M, Casadei N, Esmer H, Saido TC, Takano J, Kahle PJ, Nixon RA, Rao MV, Melki R, Pieri L, Helling S, Marcus K, Krueger R, Masliah E, Riess O, Nuber S (2014) Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-synuclein processing, aggregation and synaptic impairment in [A30P]\u03b1Syn transgenic mice. Hum Mol Genet 23(15):3975\u20133989","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1911_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092098","volume":"9","author":"H Dimant","year":"2014","unstructured":"Dimant H, Zhu L, Kibuuka LN, Fan Z, Hyman BT, McLean PJ (2014) Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One 9(3):e92098","journal-title":"PLoS One"},{"issue":"1","key":"1911_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1523\/JNEUROSCI.3442-11.2012","volume":"32","author":"G Donmez","year":"2012","unstructured":"Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L (2012) SIRT1 protects against \u03b1-synuclein aggregation by activating molecular chaperones. J Neurosci 32(1):124\u2013132","journal-title":"J Neurosci"},{"issue":"11","key":"1911_CR39","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, Ansha MG, Brayne C, Choi J-YJ, Collado-Mateo D, Dahodwala N, Do HP, Edessa D, Endres M, Fereshtehnejad S-M, Foreman KJ, Gankpe FG, Gupta R, Hankey GJ, Hay SI (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939\u2013953","journal-title":"Lancet Neurol"},{"issue":"17","key":"1911_CR40","doi-asserted-by":"publisher","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","volume":"285","author":"E Doxakis","year":"2010","unstructured":"Doxakis E (2010) Post-transcriptional regulation of \u03b1-synuclein expression by miR-7 and miR-153. J Biol Chem 285(17):12726\u201312734","journal-title":"J Biol Chem"},{"issue":"1","key":"1911_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-017-0186-8","volume":"12","author":"JA Duce","year":"2017","unstructured":"Duce JA, Wong BX, Durham H, Devedjian J-C, Smith DP, Devos D (2017) Post translational changes to \u03b1-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson\u2019s disease. Mol Neurodegener 12(1):45","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1911_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4161\/auto.8.2.18938","volume":"8","author":"D Ebrahimi-Fakhari","year":"2012","unstructured":"Ebrahimi-Fakhari D, McLean PJ, Unni VK (2012) Alpha-synuclein\u2019s degradation in vivo. Autophagy 8(2):281\u2013283","journal-title":"Autophagy"},{"issue":"10","key":"1911_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252635","volume":"16","author":"S Elfarrash","year":"2021","unstructured":"Elfarrash S, Jensen NM, Ferreira N, Schmidt SI, Gregersen E, Vestergaard MV, Nabavi S, Meyer M, Jensen PH (2021) Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein. PLoS ONE 16(10):e0252635","journal-title":"PLoS ONE"},{"issue":"3","key":"1911_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.227587","volume":"355","author":"MJ Fell","year":"2015","unstructured":"Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, Zhou X, Parker EM, Kennedy ME, Morrow JA (2015) MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. J Pharmacol Exp Ther 355(3):397\u2013409","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1911_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41531-022-00380-1","volume":"8","author":"L Fonseca-Ornelas","year":"2022","unstructured":"Fonseca-Ornelas L, Stricker JMS, Soriano-Cruz S, Weykopf B, Dettmer U, Muratore CR, Scherzer CR, Selkoe DJ (2022) Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous \u03b1-synuclein in human neurons. NPJ Parkinsons Dis 8(1):128","journal-title":"NPJ Parkinsons Dis"},{"issue":"S1","key":"1911_CR46","doi-asserted-by":"publisher","first-page":"0R494","DOI":"10.1096\/fasebj.2022.36.S1.0R494","volume":"36","author":"JS Fortin","year":"2022","unstructured":"Fortin JS, McCarty AM, Penticoff HB, Hetak AA (2022) Understanding alpha-synuclein aggregation propensity with a fragment peptide library. FASEB J 36(S1):0R494","journal-title":"FASEB J"},{"key":"1911_CR47","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fphar.2020.00776","volume":"11","author":"P Gan","year":"2020","unstructured":"Gan P, Ding L, Hang G, Xia Q, Huang Z, Ye X, Qian X (2020) Oxymatrine attenuates dopaminergic neuronal damage and microglia-mediated neuroinflammation through cathepsin D-dependent HMGB1\/TLR4\/NF-\u03baB pathway in Parkinson\u2019s disease. Front Pharmacol 11:776","journal-title":"Front Pharmacol"},{"issue":"21","key":"1911_CR48","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401352R","volume":"38","author":"J Gao","year":"2024","unstructured":"Gao J, Lin M, Qing J, Li H, Zeng X, Yuan W, Li T, He S (2024) HSP70 promotes amino acid-dependent mTORC1 signaling by mediating CHIP-induced NPRL2 ubiquitination and degradation. FASEB J 38(21):e202401352R","journal-title":"FASEB J"},{"issue":"Pt 7","key":"1911_CR49","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/brain\/awq132","volume":"133","author":"P Garcia-Reitb\u00f6ck","year":"2010","unstructured":"Garcia-Reitb\u00f6ck P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E, Ghetti B, Della Corte L, Spano P, Tofaris GK, Goedert M, Spillantini MG (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson\u2019s disease. Brain 133(Pt 7):2032\u20132044","journal-title":"Brain"},{"issue":"1","key":"1911_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13024-023-00686-5","volume":"18","author":"L Geng","year":"2023","unstructured":"Geng L, Gao W, Saiyin H, Li Y, Zeng Y, Zhang Z, Li X, Liu Z, Gao Q, An P, Jiang N, Yu X, Chen X, Li S, Chen L, Lu B, Li A, Chen G, Shen Y, Zhang H (2023) MLKL deficiency alleviates neuroinflammation and motor deficits in the \u03b1-synuclein transgenic mouse model of Parkinson\u2019s disease. Mol Neurodegener 18(1):94","journal-title":"Mol Neurodegener"},{"issue":"1","key":"1911_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-018-0245-9","volume":"13","author":"JE Gerson","year":"2018","unstructured":"Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, Barrett A, Kayed R (2018) Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener 13(1):13","journal-title":"Mol Neurodegener"},{"issue":"15","key":"1911_CR52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem SS, Majbour NK, Vaikath NN, Ardah MT, Erskine D, Jensen NM, Fayyad M, Sudhakaran IP, Vasili E, Melachroinou K, Abdi IY, Poggiolini I, Santos P, Dorn A, Carloni P, Vekrellis K, Attems J, McKeith IG, Outeiro TF, Jensen PH (2022) \u03b1-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci U S A 119(15):e2109617119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1911_CR53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"M G\u00f3mez-Benito","year":"2020","unstructured":"G\u00f3mez-Benito M, Granado N, Garc\u00eda-Sanz P, Michel A, Dumoulin M, Moratalla R (2020) Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front Pharmacol 11:356","journal-title":"Front Pharmacol"},{"issue":"3","key":"1911_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.6026\/973206300200217","volume":"20","author":"A Grewal","year":"2024","unstructured":"Grewal A, Sheokand D, Saini V, Kumar A (2024) Molecular docking analysis of \u03b1-synuclein aggregation with Anle138b. Bioinformation 20(3):217\u2013222","journal-title":"Bioinformation"},{"issue":"1","key":"1911_CR55","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","volume":"74","author":"H Grosso Jasutkar","year":"2022","unstructured":"Grosso Jasutkar H, Oh SE, Mouradian MM (2022) Therapeutics in the pipeline targeting \u03b1-synuclein for Parkinson\u2019s disease. Pharmacol Rev 74(1):207\u2013237","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1911_CR56","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41467-025-56728-7","volume":"16","author":"M Han","year":"2025","unstructured":"Han M, Frieg B, Matthes D, Leonov A, Ryazanov S, Giller K, Nimerovsky E, Stampolaki M, Xue K, Overkamp K, Dienemann C, Riedel D, Giese A, Becker S, de Groot BL, Schr\u00f6der GF, Andreas LB, Griesinger C (2025) Anle138b binds predominantly to the central cavity in lipidic A\u03b240 fibrils and modulates fibril formation. Nat Commun 16(1):2699","journal-title":"Nat Commun"},{"issue":"1","key":"1911_CR57","doi-asserted-by":"publisher","first-page":"16164","DOI":"10.1038\/s41598-018-35729-1","volume":"8","author":"GW Hassen","year":"2018","unstructured":"Hassen GW, Kesner L, Stracher A, Shulman A, Rockenstein E, Mante M, Adame A, Overk C, Rissman RA, Masliah E (2018) Effects of novel calpain inhibitors in transgenic animal model of Parkinson\u2019s disease\/dementia with Lewy bodies. Sci Rep 8(1):16164","journal-title":"Sci Rep"},{"key":"1911_CR58","doi-asserted-by":"crossref","unstructured":"Hatano T, Hattori N (2011) Etiology and pathogenesis of Parkinson\u2019s disease. Etiology Pathophysiology Parkinsons Dis. Chapter 1","DOI":"10.5772\/20050"},{"issue":"6","key":"1911_CR59","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s11064-022-03560-w","volume":"47","author":"L He","year":"2022","unstructured":"He L, Wang J, Yang Y, Li J, Tu H (2022) Mitochondrial sirtuins in Parkinson\u2019s disease. Neurochem Res 47(6):1491\u20131502","journal-title":"Neurochem Res"},{"issue":"2","key":"1911_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.27562","volume":"34","author":"A Heras-Garvin","year":"2018","unstructured":"Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N (2018) Anle138b modulates \u03b1-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord 34(2):255\u2013263","journal-title":"Mov Disord"},{"issue":"1","key":"1911_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","volume":"15","author":"BA Hijaz","year":"2020","unstructured":"Hijaz BA, Volpicelli-Daley LA (2020) Initiation and propagation of \u03b1-synuclein aggregation in the nervous system. Mol Neurodegener 15(1):19","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1911_CR62","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41589-023-01506-z","volume":"20","author":"RI Horne","year":"2024","unstructured":"Horne RI, Andrzejewska EA, Alam P, Brotzakis ZF, Srivastava A, Aubert A, Nowinska M, Gregory RC, Staats R, Possenti A, Chia S, Sormanni P, Ghetti B, Caughey B, Knowles TPJ, Vendruscolo M (2024) Discovery of potent inhibitors of \u03b1-synuclein aggregation using structure-based iterative learning. Nat Chem Biol 20(5):662\u2013673","journal-title":"Nat Chem Biol"},{"issue":"3","key":"1911_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.30773\/pi.2022.0327","volume":"20","author":"S Huh","year":"2023","unstructured":"Huh S, Yu HS, Kang N, Ahn YM, Kim YS, Kim SH (2023) Electroconvulsive seizure normalizes motor deficits and induces autophagy signaling in the MPTP-induced Parkinson disease mouse model. Psychiatry Investig 20(3):273\u2013283","journal-title":"Psychiatry Investig"},{"issue":"11","key":"1911_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112344","volume":"9","author":"L Iannotta","year":"2020","unstructured":"Iannotta L, Biosa A, Kluss JH, Tombesi G, Kaganovich A, Cogo S, Plotegher N, Civiero L, Lobbestael E, Baekelandt V, Cookson MR, Greggio E (2020) Divergent effects of G2019S and R1441C LRRK2 mutations on LRRK2 and Rab10 phosphorylations in mouse tissues. Cells 9(11):2344","journal-title":"Cells"},{"key":"1911_CR65","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnins.2016.00408","volume":"10","author":"M Ingelsson","year":"2016","unstructured":"Ingelsson M (2016) Alpha-synuclein oligomers\u2014neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders. Front Neurosci 10:408","journal-title":"Front Neurosci"},{"key":"1911_CR66","doi-asserted-by":"publisher","first-page":"1003997","DOI":"10.3389\/fnins.2022.1003997","volume":"16","author":"A Iyer","year":"2022","unstructured":"Iyer A, Sidhu A, Subramaniam V (2022) How important is the N-terminal acetylation of alpha-synuclein for its function and aggregation into amyloids? Front Neurosci 16:1003997","journal-title":"Front Neurosci"},{"issue":"648","key":"1911_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D (2022) Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med 14(648):eabj2658","journal-title":"Sci Transl Med"},{"issue":"12","key":"1911_CR68","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1021\/acschemneuro.7b00261","volume":"8","author":"NN Jha","year":"2017","unstructured":"Jha NN, Kumar R, Panigrahi R, Navalkar A, Ghosh D, Sahay S, Mondal M, Kumar A, Maji SK (2017) Comparison of \u03b1-synuclein fibril inhibition by four different amyloid inhibitors. ACS Chem Neurosci 8(12):2722\u20132733","journal-title":"ACS Chem Neurosci"},{"issue":"5","key":"1911_CR69","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1021\/acs.biochem.7b01090","volume":"57","author":"NN Jha","year":"2018","unstructured":"Jha NN, Ranganathan S, Kumar R, Mehra S, Panigrahi R, Navalkar A, Ghosh D, Kumar A, Padinhateeri R, Maji SK (2018) Complexation of NAC-derived peptide ligands with the C-terminus of \u03b1-synuclein accelerates its aggregation. Biochemistry 57(5):791\u2013804","journal-title":"Biochemistry"},{"issue":"4","key":"1911_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/09727531231191661","volume":"31","author":"S Kartik","year":"2023","unstructured":"Kartik S, Pal R, Chaudhary MJ, Nath R, Kumar M (2023) Modulation of autophagy and nitric oxide signaling via glycyrrhizic acid and 7-nitroindazole in MPTP-induced Parkinson\u2019s disease model. Ann Neurosci 31(4):265\u2013276","journal-title":"Ann Neurosci"},{"issue":"11","key":"1911_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116216","volume":"23","author":"I Kawahata","year":"2022","unstructured":"Kawahata I, Finkelstein DI, Fukunaga K (2022) Pathogenic impact of \u03b1-synuclein phosphorylation and its kinases in \u03b1-synucleinopathies. Int J Mol Sci 23(11):6216","journal-title":"Int J Mol Sci"},{"key":"1911_CR72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fncel.2012.00063","volume":"6","author":"RS Khan","year":"2012","unstructured":"Khan RS, Fonseca-Kelly Z, Callinan C, Zuo L, Sachdeva MM, Shindler KS (2012) SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci 6:63","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"1911_CR73","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s11064-021-03521-9","volume":"47","author":"H Khan","year":"2022","unstructured":"Khan H, Garg N, Singh TG, Kaur A, Thapa K (2022) Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases. Neurochem Res 47(5):1125\u20131149","journal-title":"Neurochem Res"},{"issue":"2","key":"1911_CR74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddv445","volume":"25","author":"E Kim","year":"2016","unstructured":"Kim E, Wang B, Sastry N, Masliah E, Nelson PT, Cai H, Liao FF (2016) NEDD4-mediated HSF1 degradation underlies \u03b1-synucleinopathy. Hum Mol Genet 25(2):211\u2013222","journal-title":"Hum Mol Genet"},{"key":"1911_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fneur.2017.00013","volume":"8","author":"YC Kim","year":"2017","unstructured":"Kim YC, Miller A, Lins LCRF, Han SW, Keiser MS, Boudreau RL, Davidson BL, Narayanan NS (2017) RNA interference of human \u03b1-synuclein in mouse. Front Neurol 8:13","journal-title":"Front Neurol"},{"issue":"1","key":"1911_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/d41573-022-00212-0","volume":"22","author":"K Kingwell","year":"2022","unstructured":"Kingwell K (2022) LRRK2-targeted Parkinson disease drug advances into phase III. Nat Rev Drug Discov 22(1):11\u201312","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"1911_CR77","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.3390\/ijms11114465","volume":"11","author":"VZ Klusa","year":"2010","unstructured":"Klusa VZ, Isajevs S, Svirina D, Pupure J, Beitnere U, Rumaks J, Svirskis S, Jansone B, Dzirkale Z, Muceniece R, Kalvinsh I, Vinters HV (2010) Neuroprotective properties of mildronate, a small molecule, in a rat model of Parkinson\u2019s disease. Int J Mol Sci 11(11):4465\u20134487","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1911_CR78","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1134\/S1819712423040116","volume":"17","author":"VH Knaryan","year":"2023","unstructured":"Knaryan VH (2023) Calpain mediated neurodegeneration in Parkinson\u2019s disease. Neurochem J 17(4):632\u2013638","journal-title":"Neurochem J"},{"issue":"1","key":"1911_CR79","volume":"17","author":"R Kniazev","year":"2025","unstructured":"Kniazev R (2025) Immunotherapy in early Parkinson\u2019s disease: a biomarker-driven trial framework for secondary prevention. Cureus 17(1):e96090","journal-title":"Cureus"},{"issue":"9","key":"1911_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/ph14090847","volume":"14","author":"\u0160 Korat","year":"2021","unstructured":"Korat \u0160, Bidesi NSR, Bonanno F, Di Nanni A, Ho\u00e0ng ANN, Herfert K, Maurer A, Battisti UM, Bowden GD, Thonon D, Vugts D, Windhorst AD, Herth MM (2021) Alpha-synuclein PET tracer development\u2014an overview about current efforts. Pharmaceuticals (Basel) 14(9):847","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1911_CR81","first-page":"1","volume":"8","author":"YM Kuo","year":"2019","unstructured":"Kuo YM, Nwankwo EI, Nussbaum RL, Rogers J, Maccecchini ML (2019) Translational inhibition of \u03b1-synuclein by Posiphen normalizes distal colon motility in transgenic Parkinson mice. Am J Neurodegener Dis 8(1):1\u201315","journal-title":"Am J Neurodegener Dis"},{"issue":"1","key":"1911_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E et al (2013) The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14(1):38\u201348","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"1911_CR83","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/hmg\/ddm363","volume":"17","author":"JT Lee","year":"2008","unstructured":"Lee JT, Wheeler TC, Li L, Chin L-S (2008) Ubiquitination of \u03b1-synuclein by Siah-1 promotes \u03b1-synuclein aggregation and apoptotic cell death. Hum Mol Genet 17(6):906\u2013917","journal-title":"Hum Mol Genet"},{"key":"1911_CR84","doi-asserted-by":"crossref","unstructured":"Levin J, Sing N, Melbourne S, Morgan A, Mariner C, Spillantini MG, Wegrzynowicz M, Dalley JW, Langer S, Ryazanov S, Leonov A, Griesinger C, Schmidt F, Weckbecker D, Prager K, Tenbusch M, Giese A (2022) Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: a randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine","DOI":"10.1016\/j.ebiom.2022.104021"},{"issue":"1","key":"1911_CR85","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2026.2645830","volume":"33","author":"J Li","year":"2026","unstructured":"Li J, Guo L, Cai W, Mei J, Liu J, Liu Y (2026) Overcoming the blood\u2013brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer\u2019s disease. Drug Deliv 33(1):2484326","journal-title":"Drug Deliv"},{"key":"1911_CR86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fnagi.2019.00372","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhang Y, Zhu K, Chi S, Wang C, Xie A (2020) Emerging role of sirtuin 2 in Parkinson\u2019s disease. Front Aging Neurosci 11:372","journal-title":"Front Aging Neurosci"},{"issue":"9","key":"1911_CR87","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw047","volume":"19","author":"M Lu","year":"2016","unstructured":"Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G (2016) Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson\u2019s disease via autophagy and mitochondrial ROS clearance. Int J Neuropsychopharmacol 19(9):pyw047","journal-title":"Int J Neuropsychopharmacol"},{"key":"1911_CR88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fnins.2020.00498","volume":"14","author":"M Madureira","year":"2020","unstructured":"Madureira M, Connor-Robson N, Wade-Martins R (2020) LRRK2: autophagy and lysosomal activity. Front Neurosci 14:498","journal-title":"Front Neurosci"},{"issue":"1","key":"1911_CR89","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13041-019-0504-x","volume":"12","author":"BR Malik","year":"2019","unstructured":"Malik BR, Maddison DC, Smith GA, Peters OM (2019) Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Mol Brain 12(1):100","journal-title":"Mol Brain"},{"key":"1911_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.585821","volume":"11","author":"R Manjula","year":"2021","unstructured":"Manjula R, Anuja K, Alcain FJ (2021) SIRT1 and SIRT2 activity control in neurodegenerative diseases. Front Pharmacol 11:585821","journal-title":"Front Pharmacol"},{"issue":"1","key":"1911_CR91","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0022-510X(95)00035-Z","volume":"131","author":"D Mantle","year":"1995","unstructured":"Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK (1995) Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer\u2019s disease, Lewy body dementia, Parkinson\u2019s disease and Huntington\u2019s disease. J Neurol Sci 131(1):65\u201370","journal-title":"J Neurol Sci"},{"issue":"1","key":"1911_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086048","volume":"9","author":"NR McFarland","year":"2014","unstructured":"McFarland NR, Dimant H, Kibuuka LN, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer MA, Fan Z, Schwarzschild MA, Hirst WD, McLean PJ (2014) Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not \u03b1-synuclein-induced neuronal cell loss. PLoS ONE 9(1):e86048","journal-title":"PLoS ONE"},{"issue":"10","key":"1911_CR93","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.ymthe.2017.08.017","volume":"25","author":"KJ McMillan","year":"2017","unstructured":"McMillan KJ, Murray TK, Bengoa-Vergniory N, Cordero-Llana O, Cooper J, Buckley A, Wade-Martins R, Uney JB, O\u2019Neill MJ, Wong LF, Caldwell MA (2017) Loss of microRNA-7 regulation leads to \u03b1-synuclein accumulation and dopaminergic neuronal loss in vivo. Mol Ther 25(10):2404\u20132414","journal-title":"Mol Ther"},{"key":"1911_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.852003","volume":"13","author":"S Menon","year":"2022","unstructured":"Menon S, Armstrong S, Hamzeh A, Visanji NP, Sardi SP, Tandon A (2022) Alpha-synuclein targeting therapeutics for Parkinson\u2019s disease and related synucleinopathies. Front Neurol 13:852003","journal-title":"Front Neurol"},{"key":"1911_CR95","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fnagi.2013.00053","volume":"5","author":"S-W Min","year":"2013","unstructured":"Min S-W, Sohn PD, Cho S-H, Swanson RA, Gan L (2013) Sirtuins in neurodegenerative diseases: an update on potential mechanisms. Front Aging Neurosci 5:53","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"1911_CR96","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/15548627.2017.1395992","volume":"14","author":"G Minakaki","year":"2018","unstructured":"Minakaki G, Menges S, Kittel A, Emmanouilidou E, Schaeffner I, Barkovits K, Bergmann A, Rockenstein E, Adame A, Marxreiter F, Mollenhauer B, Galasko D, Buz\u00e1s EI, Schl\u00f6tzer-Schrehardt U, Marcus K, Xiang W, Lie DC, Vekrellis K, Masliah E, Winkler J (2018) Autophagy inhibition promotes SNCA\/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. Autophagy 14(1):98\u2013119","journal-title":"Autophagy"},{"issue":"5","key":"1911_CR97","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s12035-023-03211-3","volume":"60","author":"K Moore","year":"2023","unstructured":"Moore K, Sengupta U, Puangmalai N, Bhatt N, Kayed R (2023) Polymorphic alpha-synuclein oligomers: characterization and differential detection with novel corresponding antibodies. Mol Neurobiol 60(5):2691\u20132705","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1911_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0154-3","volume":"12","author":"TE Moors","year":"2017","unstructured":"Moors TE, Hoozemans JJM, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin M-C, van de Berg WDJ (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson\u2019s disease. Mol Neurodegener 12(1):11","journal-title":"Mol Neurodegener"},{"issue":"5","key":"1911_CR99","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/jppr.1683","volume":"50","author":"N Mouchaileh","year":"2020","unstructured":"Mouchaileh N, Hughes AJ (2020) Pharmacological management of Parkinson\u2019s disease in older people. J Pharm Pract Res 50(5):445\u2013454","journal-title":"J Pharm Pract Res"},{"key":"1911_CR100","doi-asserted-by":"publisher","first-page":"100119","DOI":"10.1016\/j.pscia.2026.100119","volume":"4","author":"YF Mustafa","year":"2026","unstructured":"Mustafa YF (2026) Artificial intelligence-driven discovery of coumarin-based therapeutics: revolutionizing target identification and validation. Pharm Sci Adv 4:100119","journal-title":"Pharm Sci Adv"},{"issue":"1","key":"1911_CR101","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s10020-021-00279-2","volume":"27","author":"T Ntetsika","year":"2021","unstructured":"Ntetsika T, Papathoma P-E, Markaki I (2021) Novel targeted therapies for Parkinson\u2019s disease. Mol Med 27(1):17","journal-title":"Mol Med"},{"issue":"5","key":"1911_CR102","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ajpath.2023.01.010","volume":"193","author":"S Nuber","year":"2023","unstructured":"Nuber S, Selkoe DJ (2023) The Parkinson-associated toxin paraquat shifts physiological \u03b1-synuclein tetramers toward monomers that can be calpain-truncated and form oligomers. Am J Pathol 193(5):520\u2013531","journal-title":"Am J Pathol"},{"issue":"11","key":"1911_CR103","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1007\/s00415-022-11267-9","volume":"269","author":"CK Nwabufo","year":"2022","unstructured":"Nwabufo CK, Aigbogun OP (2022) Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson\u2019s disease. J Neurol 269(11):5762\u20135786","journal-title":"J Neurol"},{"issue":"1","key":"1911_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06548-2","volume":"15","author":"J Okarmus","year":"2024","unstructured":"Okarmus J, Agergaard JB, Stummann TC, Haukedal H, Ambj\u00f8rn M, Freude KK, Fog K, Meyer M (2024) USP30 inhibition induces mitophagy and reduces oxidative stress in parkin-deficient human neurons. Cell Death Dis 15(1):157","journal-title":"Cell Death Dis"},{"issue":"19","key":"1911_CR105","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1523\/JNEUROSCI.0959-12.2012","volume":"32","author":"N Oosterhof","year":"2012","unstructured":"Oosterhof N, Dekens DW, Lawerman TF, van Dijk M (2012) Yet another role for SIRT1: reduction of \u03b1-synuclein aggregation in stressed neurons. J Neurosci 32(19):6413\u20136414","journal-title":"J Neurosci"},{"issue":"1","key":"1911_CR106","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2020.8401","volume":"12","author":"JL Orozco","year":"2020","unstructured":"Orozco JL, Valderrama-Chaparro JA, Pinilla-Monsalve GD, Molina-Echeverry MI, P\u00e9rez Casta\u00f1o AM, Ariza-Ara\u00fajo Y, Prada SI, Takeuchi Y (2020) Parkinson\u2019s disease prevalence, age distribution and staging in Colombia. Neurol Int 12(1):8401","journal-title":"Neurol Int"},{"issue":"1","key":"1911_CR107","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JPD-160779","volume":"6","author":"A Oueslati","year":"2016","unstructured":"Oueslati A (2016) Implication of alpha-synuclein phosphorylation at S129 in synucleinopathies: what have we learned in the last decade? J Parkinsons Dis 6(1):39\u201351","journal-title":"J Parkinsons Dis"},{"issue":"41","key":"1911_CR108","doi-asserted-by":"publisher","first-page":"E3945","DOI":"10.1073\/pnas.1309991110","volume":"110","author":"A Oueslati","year":"2013","unstructured":"Oueslati A, Schneider BL, Aebischer P, Lashuel HA (2013) Polo-like kinase 2 regulates selective autophagic \u03b1-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A 110(41):E3945\u2013E3954","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1911_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2025.1570553","volume":"19","author":"FJ Padilla-God\u00ednez","year":"2025","unstructured":"Padilla-God\u00ednez FJ, V\u00e1zquez-Garc\u00eda ER, Trujillo-Villagr\u00e1n MI, Soto-Rojas LO, Palomero-Rivero M, Hern\u00e1ndez-Gonz\u00e1lez O, P\u00e9rez-Eugenio F, Collazo-Navarrete O, Arias-Carri\u00f3n O, Guerra-Crespo M (2025) \u03b1-synuclein and tau: interactions, cross-seeding, and the redefinition of synucleinopathies as complex proteinopathies. Front Neurosci 19:1570553","journal-title":"Front Neurosci"},{"key":"1911_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.705407","volume":"12","author":"G Pagano","year":"2021","unstructured":"Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K (2021) A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson\u2019s disease (PASADENA): rationale, design, and baseline data. Front Neurol 12:705407","journal-title":"Front Neurol"},{"key":"1911_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"6","key":"1911_CR112","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/jnc.15174","volume":"156","author":"M Pantazopoulou","year":"2020","unstructured":"Pantazopoulou M, Brembati V, Kanellidi A, Bousset L, Melki R, Stefanis L (2020) Distinct alpha-synuclein species induced by seeding are selectively cleared by the lysosome or the proteasome in neuronally differentiated SH-SY5Y cells. J Neurochem 156(6):880\u2013896","journal-title":"J Neurochem"},{"issue":"6","key":"1911_CR113","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1159\/000107702","volume":"4","author":"S Papapetropoulos","year":"2007","unstructured":"Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E (2007) A prospective study of familial versus sporadic Parkinson\u2019s disease. Neurodegener Dis 4(6):424\u2013427","journal-title":"Neurodegener Dis"},{"key":"1911_CR114","doi-asserted-by":"crossref","unstructured":"Pastic A, Negeri O, Ravel-Chapuis A, Savard A, Trung MT, Palidwor G, Guo H, Marcogliese P, Taylor JA, Okano H, Trinkle-Mulcahy L, Jasmin BJ, Park D, Gibbings D (2022) LRRK2 phosphorylates neuronal ELAV RNA-binding proteins to regulate phenotypes relevant to Parkinson\u2019s disease. bioRxiv","DOI":"10.1101\/2022.04.24.489327"},{"issue":"7556","key":"1911_CR115","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"W Peelaerts","year":"2015","unstructured":"Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V (2015) \u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522(7556):340\u2013344","journal-title":"Nature"},{"issue":"5","key":"1911_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101902","volume":"298","author":"S Pe\u00f1a-D\u00edaz","year":"2022","unstructured":"Pe\u00f1a-D\u00edaz S, Pujols J, Vasili E, Pinheiro F, Santos JB, Manglano-Artu\u00f1edo Z, Outeiro TF, Ventura S (2022) The small aromatic compound SynuClean-D inhibits the aggregation and seeded polymerization of multiple \u03b1-synuclein strains. J Biol Chem 298(5):101902","journal-title":"J Biol Chem"},{"issue":"8","key":"1911_CR117","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1523\/JNEUROSCI.22-08-03090.2002","volume":"22","author":"RG Perez","year":"2002","unstructured":"Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for \u03b1-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22(8):3090\u20133099","journal-title":"J Neurosci"},{"key":"1911_CR118","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fnmol.2018.00412","volume":"11","author":"A Pi\u0161lar","year":"2018","unstructured":"Pi\u0161lar A, Tratnjek L, Glavan G, \u017divin M, Kos J (2018) Upregulation of cysteine protease cathepsin X in the 6-hydroxydopamine model of Parkinson\u2019s disease. Front Mol Neurosci 11:412","journal-title":"Front Mol Neurosci"},{"issue":"14","key":"1911_CR119","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1523\/JNEUROSCI.0610-22.2023","volume":"43","author":"C Pitcairn","year":"2023","unstructured":"Pitcairn C, Murata N, Zalon A, Stojkovska I, Mazzulli JR (2023) Impaired autophagic-lysosomal fusion in Parkinson\u2019s patient midbrain neurons occurs through loss of ykt6 and is rescued by farnesyltransferase inhibition. J Neurosci 43(14):2615\u20132629","journal-title":"J Neurosci"},{"key":"1911_CR120","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013","journal-title":"Nat Rev Dis Primers"},{"key":"1911_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.659926","volume":"14","author":"B Popova","year":"2021","unstructured":"Popova B, Wang D, Rajavel A, Dhamotharan K, L\u00e1zaro DF, Gerke J, Uhrig JF, Hoppert M, Outeiro TF, Braus GH (2021) Identification of two novel peptides that inhibit \u03b1-synuclein toxicity and aggregation. Front Mol Neurosci 14:659926","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"1911_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, Bonhaus D (2018) The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep 8(1):16165","journal-title":"Sci Rep"},{"issue":"1","key":"1911_CR123","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41531-023-00552-7","volume":"9","author":"DL Price","year":"2023","unstructured":"Price DL, Khan A, Angers R, Cardenas A, Prato MK, Bani M, Bonhaus DW, Citron M, Biere AL (2023) In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease. NPJ Parkinsons Dis 9(1):114","journal-title":"NPJ Parkinsons Dis"},{"issue":"13","key":"1911_CR124","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TDL (2014) The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 29(13):1583\u20131590","journal-title":"Mov Disord"},{"issue":"41","key":"1911_CR125","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"J Pujols","year":"2018","unstructured":"Pujols J, Pe\u00f1a-D\u00edaz S, L\u00e1zaro DF, Peccati F, Pinheiro F, Gonz\u00e1lez D, Carija A, Navarro S, Conde-Gim\u00e9nez M, Garc\u00eda J, Guardiola S, Giralt E, Salvatella X, Sancho J, Sodupe M, Outeiro TF, Dalf\u00f3 E, Ventura S (2018) Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci U S A 115(41):10481\u201310486","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1911_CR126","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neulet.2009.12.055","volume":"470","author":"J Pupure","year":"2010","unstructured":"Pupure J, Isajevs S, Skapare E, Rumaks J, Svirskis S, Svirina D, Kalvinsh I, Klusa V (2010) Neuroprotective properties of mildronate, a mitochondria-targeted small molecule. Neurosci Lett 470(2):100\u2013105","journal-title":"Neurosci Lett"},{"issue":"4","key":"1911_CR127","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10517-021-05242-z","volume":"171","author":"AB Pupyshev","year":"2021","unstructured":"Pupyshev AB, Tenditnik MV, Ovsyukova MV, Akopyan AA, Dubrovina NI, Tikhonova MA (2021) Restoration of Parkinson\u2019s disease-like deficits by activating autophagy through mTOR-dependent and mTOR-independent mechanisms in pharmacological and transgenic models of Parkinson\u2019s disease in mice. Bull Exp Biol Med 171(4):425\u2013430","journal-title":"Bull Exp Biol Med"},{"issue":"3","key":"1911_CR128","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1124\/jpet.109.158436","volume":"332","author":"P Putcha","year":"2009","unstructured":"Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, McLean PJ (2009) Brain-permeable small-molecule inhibitors of Hsp90 prevent \u03b1-synuclein oligomer formation and rescue \u03b1-synuclein-induced toxicity. J Pharmacol Exp Ther 332(3):849\u2013857","journal-title":"J Pharmacol Exp Ther"},{"key":"1911_CR129","doi-asserted-by":"publisher","DOI":"10.1007\/s43538-024-00325-7","author":"P Rai","year":"2024","unstructured":"Rai P (2024) Conformational dynamics of Hsp90 and Hsp70 chaperones in treating neurodegenerative diseases: insights from the Drosophila model. Proc Indian Natl Sci Acad. https:\/\/doi.org\/10.1007\/s43538-024-00325-7","journal-title":"Proc Indian Natl Sci Acad"},{"issue":"1","key":"1911_CR130","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13024-023-00680-x","volume":"18","author":"N Ramalingam","year":"2023","unstructured":"Ramalingam N, Dettmer U (2023) \u03b1-Synuclein serine129 phosphorylation \u2013 the physiology of pathology. Mol Neurodegener 18(1):88","journal-title":"Mol Neurodegener"},{"issue":"7","key":"1911_CR131","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.tins.2024.05.005","volume":"47","author":"N Ramalingam","year":"2024","unstructured":"Ramalingam N, Haass C, Dettmer U (2024) Physiological roles of \u03b1-synuclein serine-129 phosphorylation \u2013 not an oxymoron. Trends Neurosci 47(7):480\u2013490","journal-title":"Trends Neurosci"},{"issue":"15","key":"1911_CR132","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1021\/acschemneuro.3c00370","volume":"14","author":"A Rodr\u00edguez-Ramos","year":"2023","unstructured":"Rodr\u00edguez-Ramos A, Gonz\u00e1lez JA, Fanarraga ML (2023) Enhanced inhibition of amyloid formation by heat shock protein 90 immobilized on nanoparticles. ACS Chem Neurosci 14(15):2811\u20132817","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"1911_CR133","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00702-010-0513-5","volume":"118","author":"JT Rogers","year":"2011","unstructured":"Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, Smith DH, Huang X, Bandyopadhyay S, Cahill CM, Maccecchini ML, Lahiri DK, Greig NH (2011) The alpha-synuclein 5\u2032 untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm (Vienna) 118(3):493\u2013507","journal-title":"J Neural Transm (Vienna)"},{"issue":"1","key":"1911_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58970-z","volume":"10","author":"M Runfola","year":"2020","unstructured":"Runfola M, De Simone A, Vendruscolo M, Dobson CM, Fusco G (2020) The N-terminal acetylation of \u03b1-synuclein changes the affinity for lipid membranes but not the structural properties of the bound state. Sci Rep 10(1):2043","journal-title":"Sci Rep"},{"issue":"1","key":"1911_CR135","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15372-w","volume":"23","author":"S Safiri","year":"2023","unstructured":"Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJM, Araj-Khodaei M, Singh K, Kolahi A-A, Gharagozli K (2023) The burden of Parkinson\u2019s disease in the Middle East and North Africa region, 1990\u20132019: results from the global burden of disease study 2019. BMC Public Health 23(1):514","journal-title":"BMC Public Health"},{"issue":"9","key":"1911_CR136","doi-asserted-by":"publisher","first-page":"e202300705","DOI":"10.1002\/cmdc.202300705","volume":"19","author":"N Sanghai","year":"2024","unstructured":"Sanghai N, Vuong B, Berk AB, Muhammad SKA, Tranmer GK (2024) Current small molecules-based medicinal chemistry approaches for neurodegeneration therapeutics. ChemMedChem 19(9):e202300705","journal-title":"ChemMedChem"},{"issue":"2","key":"1911_CR137","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1515\/revneuro-2012-0071","volume":"24","author":"H Sato","year":"2013","unstructured":"Sato H, Kato T, Arawaka S (2013) The role of Ser129 phosphorylation of \u03b1-synuclein in neurodegeneration of Parkinson\u2019s disease: a review of in vivo models. Rev Neurosci 24(2):115\u2013123","journal-title":"Rev Neurosci"},{"issue":"1","key":"1911_CR138","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13024-020-00370-y","volume":"15","author":"M Schechter","year":"2020","unstructured":"Schechter M, Grigoletto J, Abd-Elhadi S, Glickstein H, Friedman A, Serrano GE, Beach TG, Sharon R (2020) A role for \u03b1-synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson\u2019s disease. Mol Neurodegener 15(1):24","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1911_CR139","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/molecules23020411","volume":"23","author":"S Schiavone","year":"2018","unstructured":"Schiavone S, Trabace L (2018) Small molecules: therapeutic application in neuropsychiatric and neurodegenerative disorders. Molecules 23(2):411","journal-title":"Molecules"},{"issue":"12","key":"1911_CR140","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1074\/mcp.R113.032730","volume":"12","author":"AW Schmid","year":"2013","unstructured":"Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteom 12(12):3543\u20133558","journal-title":"Mol Cell Proteom"},{"issue":"1","key":"1911_CR141","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1007\/s12035-021-02596-3","volume":"59","author":"IN Serratos","year":"2022","unstructured":"Serratos IN, Hern\u00e1ndez-P\u00e9rez E, Campos C, Aschner M, Santamar\u00eda A (2022) An update on the critical role of \u03b1-synuclein in Parkinson\u2019s disease and other synucleinopathies: from tissue to cellular and molecular levels. Mol Neurobiol 59(1):620\u2013642","journal-title":"Mol Neurobiol"},{"issue":"1","key":"1911_CR142","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12868-017-0364-1","volume":"18","author":"P Singh","year":"2017","unstructured":"Singh P, Hanson PS, Morris CM (2017) SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson\u2019s disease. BMC Neurosci 18(1):46","journal-title":"BMC Neurosci"},{"issue":"4","key":"1911_CR143","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s11030-020-10116-z","volume":"25","author":"AP Singh","year":"2021","unstructured":"Singh AP, Nigam L, Yadav Y, Shekhar S, Subbarao N, Dey S (2021) Design and in vitro analysis of SIRT2 inhibitor targeting Parkinson\u2019s disease. Mol Divers 25(4):2261\u20132270","journal-title":"Mol Divers"},{"issue":"1","key":"1911_CR144","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/ijerph19010364","volume":"19","author":"P Sivanandy","year":"2021","unstructured":"Sivanandy P, Leey TC, Xiang TC, Ling TC, Han SAW, Semilan SLA, Hong PK (2021) Systematic review on Parkinson\u2019s disease medications, emphasizing on three recently approved drugs to control Parkinson\u2019s symptoms. Int J Environ Res Public Health 19(1):364","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"1911_CR145","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/pharmaceutics15082051","volume":"15","author":"N Siwecka","year":"2023","unstructured":"Siwecka N, Saramowicz K, Galita G, Rozp\u0119dek-Kami\u0144ska W, Majsterek I (2023) Inhibition of protein aggregation and endoplasmic reticulum stress as a targeted therapy for \u03b1-synucleinopathy. Pharmaceutics 15(8):2051","journal-title":"Pharmaceutics"},{"issue":"10","key":"1911_CR146","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, Basile P, Prato MK, Detalle L, Mathy F, Schmidt A, Lalla M, Germani M, Domange C, Biere A, Bani M, Carson S, Genius J (2022) Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov Disord 37(10):2045\u20132056","journal-title":"Mov Disord"},{"key":"1911_CR147","doi-asserted-by":"publisher","first-page":"1314077","DOI":"10.3389\/fddsv.2023.1314077","volume":"3","author":"M Southey","year":"2023","unstructured":"Southey M, Brunavs M (2023) Introduction to small molecule drug discovery and preclinical development. Front Drug Discov 3:1314077","journal-title":"Front Drug Discov"},{"issue":"S1","key":"1911_CR148","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1002\/mds.22639","volume":"25","author":"D Sulzer","year":"2010","unstructured":"Sulzer D (2010) Clues to how alpha-synuclein damages neurons in Parkinson\u2019s disease. Mov Disord 25(S1):S27\u2013S31","journal-title":"Mov Disord"},{"issue":"S1","key":"1911_CR149","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S (2016) The clinical symptoms of Parkinson\u2019s disease. J Neurochem 139(S1):318\u2013324","journal-title":"J Neurochem"},{"issue":"1","key":"1911_CR150","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1134\/S0012496616010117","volume":"466","author":"TV Tarasova","year":"2016","unstructured":"Tarasova TV, Lytkina OA, Roman AYu, Bachurin SO, Ustyugov AA (2016) The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area. Dokl Biol Sci 466(1):5\u20137","journal-title":"Dokl Biol Sci"},{"issue":"3","key":"1911_CR151","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/biom10030391","volume":"10","author":"M Teil","year":"2020","unstructured":"Teil M, Arotcarena M-L, Faggiani E, Laferriere F, Bezard E, Dehay B (2020) Targeting \u03b1-synuclein for PD therapeutics: a pursuit on all fronts. Biomolecules 10(3):391","journal-title":"Biomolecules"},{"issue":"2","key":"1911_CR152","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","volume":"16","author":"E Tolosa","year":"2020","unstructured":"Tolosa E, Vila M, Klein C, Rascol O (2020) LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol 16(2):97\u2013107","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1911_CR153","doi-asserted-by":"publisher","first-page":"e2306682120","DOI":"10.1073\/pnas.2306682120","volume":"121","author":"Y Tong","year":"2024","unstructured":"Tong Y, Zhang P, Yang X, Liu X, Zhang J, Grudniewska M, Jung I, Abegg D, Li J, Childs-Disney JL, Haniff HS, Adibekian A, Mouradian MM, Disney MD (2024) Decreasing the intrinsically disordered protein \u03b1-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera. Proc Natl Acad Sci U S A 121(2):e2306682120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1911_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087133","volume":"9","author":"G T\u00f3th","year":"2014","unstructured":"T\u00f3th G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet J-C, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou S-S, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA (2014) Targeting the intrinsically disordered structural ensemble of \u03b1-synuclein by small molecules as a potential therapeutic strategy for Parkinson\u2019s disease. PLoS ONE 9(2):e87133","journal-title":"PLoS ONE"},{"issue":"23","key":"1911_CR155","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1042\/BCJ20210508","volume":"478","author":"E Tsefou","year":"2021","unstructured":"Tsefou E, Walker AS, Clark EH, Hicks AR, Luft C, Takeda K, Watanabe T, Ramazio B, Staddon JM, Briston T, Ketteler R (2021) Investigation of USP30 inhibition to enhance Parkin-mediated mitophagy: tools and approaches. Biochem J 478(23):4099\u20134118","journal-title":"Biochem J"},{"issue":"3","key":"1911_CR156","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1055\/s-0045-1805075","volume":"83","author":"V Tumas","year":"2025","unstructured":"Tumas V, Aureliano MJ, Roberto C, Schumacher F, Ferraz HB, Borges V, Soares MC, Boone DL, Candeias C, Costa MC, Silva V, Santos-Lobato BL, Lucia A, Braga-Neto P, Borges A, Gon\u00e7alves C, Letro GH (2025) Modifiable risk factors associated with the risk of developing Parkinson\u2019s disease: a critical review. Arq Neuropsiquiatr 83(3):001\u2013010","journal-title":"Arq Neuropsiquiatr"},{"key":"1911_CR157","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1471-4159.2007.04764.x","volume":"103","author":"VN Uversky","year":"2007","unstructured":"Uversky VN (2007) Neuropathology, biochemistry, and biophysics of \u03b1-synuclein aggregation. J Neurochem 103:17\u201337","journal-title":"J Neurochem"},{"issue":"23","key":"1911_CR158","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314630","volume":"23","author":"N Vaikath","year":"2022","unstructured":"Vaikath N, Sudhakaran I, Abdi I, Gupta V, Majbour N, Ghanem S, Abdesselem H, Vekrellis K, El-Agnaf O (2022) Structural and biophysical characterization of stable alpha-synuclein oligomers. Int J Mol Sci 23(23):14630","journal-title":"Int J Mol Sci"},{"key":"1911_CR159","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fnmol.2016.00048","volume":"9","author":"C Wang","year":"2016","unstructured":"Wang C, Zhao C, Li D, Tian Z, Lai Y, Diao J, Liu C (2016) Versatile structures of \u03b1-synuclein. Front Mol Neurosci 9:48","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"1911_CR160","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/mds.29043","volume":"37","author":"S Wang","year":"2022","unstructured":"Wang S, Unnithan S, Bryant N, Chang A, Rosenthal LS, Pantelyat A, Dawson TM, Al-Khalidi HR, West AB (2022a) Elevated urinary Rab10 phosphorylation in idiopathic Parkinson disease. Mov Disord 37(7):1454\u20131464","journal-title":"Mov Disord"},{"key":"1911_CR161","doi-asserted-by":"publisher","first-page":"977521","DOI":"10.3389\/fphar.2022.977521","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wu S, Li Q, Lang W, Li W, Jiang X, Wan Z, Chen J, Wang H (2022b) Epigallocatechin-3-gallate: a phytochemical as a promising drug candidate for the treatment of Parkinson\u2019s disease. Front Pharmacol 13:977521","journal-title":"Front Pharmacol"},{"key":"1911_CR162","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.97228","volume":"13","author":"C Wang","year":"2024","unstructured":"Wang C, Zhao C, Xiao H, Qiang J, Liu Z, Gu J, Zhang S, Li D, Zhang Y, Burr\u00e9 J, Diao J, Liu C (2024) N-acetylation of \u03b1-synuclein enhances synaptic vesicle clustering mediated by \u03b1-synuclein and lysophosphatidylcholine. eLife 13:e97228","journal-title":"eLife"},{"issue":"27","key":"1911_CR163","doi-asserted-by":"publisher","first-page":"25009","DOI":"10.1074\/jbc.M300227200","volume":"278","author":"JL Webb","year":"2003","unstructured":"Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) \u03b1-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278(27):25009\u201325013","journal-title":"J Biol Chem"},{"issue":"11","key":"1911_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28114458","volume":"28","author":"T Wen","year":"2023","unstructured":"Wen T, Chen J, Zhang W, Pang J (2023) Design, synthesis and biological evaluation of \u03b1-synuclein proteolysis-targeting chimeras. Molecules 28(11):4458","journal-title":"Molecules"},{"issue":"17","key":"1911_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713199","volume":"24","author":"MJ Wojewska","year":"2023","unstructured":"Wojewska MJ, Otero-Jimenez M, Guijarro-Nuez J, Alegre-Abarrategui J (2023) Beyond strains: molecular diversity in alpha-synuclein at the center of disease heterogeneity. Int J Mol Sci 24(17):13199","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1911_CR166","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1016\/j.apsb.2022.11.007","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yang Z, Cheng K, Bi H, Chen J (2022) Small molecule-based immunomodulators for cancer therapy. Acta Pharm Sin B 12(12):4287\u20134308","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"1911_CR167","first-page":"12885","volume":"8","author":"J Xu","year":"2015","unstructured":"Xu J, Zhang X-Z, Zhang Y-J, Li X-M, Cai Z-L, Li X-M (2015) Silencing of SIAH1 in SH-SY5Y affects \u03b1-synuclein degradation pathway. Int J Clin Exp Pathol 8(10):12885\u201312894","journal-title":"Int J Clin Exp Pathol"},{"key":"1911_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.biosystems.2023.105036","volume":"233","author":"B Yang","year":"2023","unstructured":"Yang B, Yang Z, Liu H, Qi H (2023) Dynamic modelling and tristability analysis of misfolded \u03b1-synuclein degraded via autophagy in Parkinson\u2019s disease. BioSystems 233:105036","journal-title":"BioSystems"},{"issue":"1","key":"1911_CR169","doi-asserted-by":"publisher","first-page":"articlenumberpe","DOI":"10.1007\/s10571-025-01544-2","volume":"45","author":"S Yaribash","year":"2025","unstructured":"Yaribash S, Mohammadi K, Sani MA (2025) Alpha-synuclein pathophysiology in neurodegenerative disorders: a review focusing on molecular mechanisms and treatment advances in Parkinson\u2019s disease. Cell Mol Neurobiol 45(1):articlenumberpending","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"1911_CR170","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/crispr.2021.0025","volume":"5","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Ye S, Lim S, Jo A, Lee H, Hong F, Lee SE, Oh S-J, Kim N-R, Kim K, Kim BJ, Kim H, Lee CJ, Nam M-H, Hur JW, Jeon SR (2022) CRISPR-Cas9 gene editing protects from the A53T-SNCA overexpression-induced pathology of Parkinson\u2019s disease in vivo. CRISPR J 5(1):95\u2013108","journal-title":"CRISPR J"},{"key":"1911_CR171","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1380483","volume":"16","author":"A Yusufujiang","year":"2024","unstructured":"Yusufujiang A, Zeng S, Li H (2024) Cathepsins and Parkinson\u2019s disease: insights from Mendelian randomization analyses. Front Aging Neurosci 16:1380483","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1911_CR172","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/10738584241232963","volume":"30","author":"AJ Zalon","year":"2024","unstructured":"Zalon AJ, Quiriconi DJ, Pitcairn C, Mazzulli JR (2024) \u03b1-Synuclein: multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson\u2019s disease. Neuroscientist 30(5):612\u2013635","journal-title":"Neuroscientist"},{"key":"1911_CR173","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fnagi.2018.00370","volume":"10","author":"G Zhang","year":"2018","unstructured":"Zhang G, Xia Y, Wan F, Ma K, Guo X, Kou L, Yin S, Han C, Liu L, Huang J, Xiong N, Wang T (2018) New perspectives on roles of alpha-synuclein in Parkinson\u2019s disease. Front Aging Neurosci 10:370","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"1911_CR174","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1073\/pnas.1905057117","volume":"117","author":"P Zhang","year":"2020","unstructured":"Zhang P, Lee H, Zhang J, Junn E, Andrews RJ, Velagapudi SP, Abegg D, Vishnu K, Costales MG, Childs-Disney JL, Adibekian A, Moss WN, Mouradian MM, Disney MD (2020) Translation of the intrinsically disordered protein \u03b1-synuclein is inhibited by a small molecule targeting its structured mRNA. Proc Natl Acad Sci U S A 117(3):1457\u20131467","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1911_CR175","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.1038\/s41467-023-42876-1","volume":"14","author":"FTS Zhang","year":"2023","unstructured":"Zhang FTS, Sun Y, Pearce AC, Eleuteri S, Kemp M, Luckhurst CA, Williams R, Mills R, Almond S, Burzynski L, M\u00e1rkus NM, Lelliott CJ, Karp NA, Adams DJ, Jackson SP, Zhao J-F, Ganley IG, Thompson PW, Balmus G, Simon DK (2023) Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson\u2019s disease mouse model. Nat Commun 14(1):7295","journal-title":"Nat Commun"},{"issue":"52","key":"1911_CR176","doi-asserted-by":"publisher","first-page":"32508","DOI":"10.1039\/C7RA03752J","volume":"7","author":"J Zhao","year":"2017","unstructured":"Zhao J, Liang Q, Sun Q, Chen C, Xu L, Ding Y, Zhou P (2017) (\u2013)-Epigallocatechin-3-gallate (EGCG) inhibits fibrillation, disaggregates amyloid fibrils of \u03b1-synuclein, and protects PC12 cells against \u03b1-synuclein-induced toxicity. RSC Adv 7(52):32508\u201332517","journal-title":"RSC Adv"},{"key":"1911_CR177","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T, Yang S (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Sig Transduct Target Ther 6:201","journal-title":"Sig Transduct Target Ther"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-026-01911-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-026-01911-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:02:28Z","timestamp":1784786548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-026-01911-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":177,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s11011-026-01911-y","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"174"}}